Review · PMID 37242459

Stable Gastric Pentadecapeptide BPC 157 May Recover Brain-Gut Axis and Gut-Brain Axis Function

2023 review by the Zagreb BPC-157 group proposing the peptide supports brain-gut and gut-brain axis function, based on animal-model findings; no human data.

Last updated · 2023 · Sikiric, P., Gojkovic, S., Krezic, I., Smoday, I.M., Kalogjera, L., Zizek, H., Oroz, K., Vranes, H., Vukovic, V., Labidi, M., Strbe, S., Baketic Oreskovic, L., Sever, M., Tepes, M., Knezevic, M., Barisic, I., Blagaic, V., Vlainic, J., Dobric, I., Staresinic, M., Skrtic, A., Jurjevic, I., Boban Blagaic, A., Seiwerth, S. · Pharmaceuticals
Key findings
  • Proposes that BPC 157's peripheral and central effects form an interconnected brain-gut and gut-brain axis network
  • Summarizes behavioral findings: anxiolytic, anticonvulsive and antidepressant effects, and counteracted catalepsy and schizophrenia-symptom models
  • Summarizes muscle healing, counteracted heart failure, arrhythmias and thrombosis, and recovered smooth muscle function
  • Describes counteracted stomach, liver and brain lesions and multiorgan failure after major vessel occlusion in rats
Where to buy BPC-157 →BioLongevity Labs · save 15% code VIALBASE

Summary

This is a narrative review, not an original experiment. Researchers from the University of Zagreb (Sikiric, Seiwerth and colleagues) argue that the wide range of effects reported for BPC 157, both in the gut and periphery and in the central nervous system, can be read as one interconnected network acting on brain-gut and gut-brain axis function. The evidence summarized comes from experimental models; the abstract reports findings in rats and describes no human studies.

Key Findings

  • Behavioral findings: interaction with the “main systems”, anxiolytic, anticonvulsive and antidepressant effects, and counteracted catalepsy and models of positive and negative schizophrenia symptoms
  • Muscle: healing and functional recovery across muscle disabilities with both peripheral and central causes; smooth muscle function recovered
  • Heart: heart failure, including arrhythmias and thrombosis, was counteracted
  • Encephalopathies: in rats given NSAIDs or insulin, BPC 157 counteracted stomach and liver lesions and various encephalopathies
  • Vessel occlusion: BPC 157 rapidly activated collateral pathways and counteracted the vascular and multiorgan failure that follows major vessel occlusion (the authors’ “occlusion/occlusion-like syndrome”), attenuating intracranial (superior sagittal sinus), portal and caval hypertension and aortal hypotension, and lesions in the brain, lungs, liver, kidney and gastrointestinal tract
  • The authors conclude by suggesting further BPC 157 therapy applications

Methodology

Narrative review synthesizing preclinical findings on BPC 157 across behavioral, muscle, cardiovascular and multiorgan injury models. The abstract does not describe a systematic search strategy.

Limitations

  • Preclinical evidence only; the abstract describes no human data
  • Written by a single research group (University of Zagreb), and the unifying brain-gut axis framework is the authors’ interpretation
  • Covers many organ systems briefly, so individual findings should be checked against the original experimental papers

Relevance to Content

Reference for BPC-157 content that goes beyond musculoskeletal healing, such as proposed gut-brain, behavioral, and neuroprotective effects. Any claims drawn from it should be framed as animal-model findings and hypotheses, not demonstrated effects in people.

See Also

Where to buy BPC-157
BPC-15712 vetted vendors

Save 15% with code VIALBASE

See all 12 sources →

VialBase may earn a commission on partner links — never at extra cost to you. Disclosure.